Urelumab
Urelumab, a fully human, non-ligand binding, CD137 agonist IgG4 monoclonal antibody, enhances T-cell and natural killer-cell antitumor activity, and may enhance cytotoxic activity of Rituximab (HY-P9913) . Urelumab can be used for the research of diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and other types of non-Hodgkin lymphoma (NHL) [1].
Product Specifications
CAS Number
[934823-49-1]
UNSPSC
12352203
Target
TNF Receptor
Type
Inhibitory Antibodies
Related Pathways
Apoptosis
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/urelumab.html
Purity
99.33
Solubility
H2O
Smiles
[Urelumab]
Molecular Weight
(145.82 kDa)
References & Citations
[1]John Timmerman, et al. Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma. Am J Hematol. 2020 May;95 (5) :510-520.|[2]Cheng LS, et al. A humanized 4-1BB-targeting agonistic antibody exerts potent antitumor activity in colorectal cancer without systemic toxicity. J Transl Med. 2022 Sep 8;20 (1) :415.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
431466 50 / PCK
Corning 175cm2 Angled Neck Not Treated Cell Culture Flask with Vent Cap
Ask
View Details 
